Biomarin Pharmaceutical Inc
Ownership
Ownership Structure
Who owns Biomarin Pharmaceutical Inc (BMRN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 99.4% of the shares are freely tradable; institutional investors hold 102.2%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 10.24 | 19,818,301 | +3.6 | 03/31/2026 |
| Dodge & Cox | 7.67 | 14,844,930 | +1.9 | 06/30/2026 |
| PRIMECAP Management Company | 7.33 | 14,190,183 | +0.0 | 06/30/2026 |
| Vanguard Capital Management, LLC | 4.47 | 8,643,164 | +0.0 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 4.29 | 8,298,475 | +0.0 | 03/31/2026 |
| NORGES BANK | 4.24 | 8,207,954 | +9.0 | 06/30/2026 |
| AQR Capital Management LLC | 3.97 | 7,676,541 | +14.8 | 03/31/2026 |
| State Street Corp | 3.77 | 7,295,079 | -3.0 | 03/31/2026 |
| Viking Global Investors LP | 3.65 | 7,062,077 | +17.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Dodge & Cox Stock I | 5.05 | 9,769,625 | +0.0 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Davis George Eric | EVP, Chief Legal Officer | 61,003 | 3,971,295 $ | Sep 2, 2026 | direct |
| Plenge Robert M | Director | 6,140 | 399,714 $ | Sep 10, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 10, 2026 | Plenge Robert M | Director | Other | 6,140 | 0.00 | – |
| Sep 2, 2026 | Davis George Eric | EVP, Chief Legal Officer | Sell | 17,557 | 66.28 | 1,163,748 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.